Treatment of prostate cancer

Details Treatment of prostate cancer Treatment of prostate cancer

2008-05-27

2008-05-27

Aulakh, Charanjit S. (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

C560S205000

Reexamination Certificate

active

11324587

ABSTRACT:
A chemical agent of the diterpene family obtained from a member of the Euphorbiaceae family of plants for use in the treatment of prophylaxis of prostate cancer or a related cancer or condition.

REFERENCES:
patent: 4418064 (1983-11-01), Powell et al.
patent: 4560774 (1985-12-01), Pettit et al.
patent: 4716179 (1987-12-01), Hecker et al.
patent: 5145842 (1992-09-01), Driedger et al.
patent: 5643948 (1997-07-01), Driedger et al.
patent: 5716968 (1998-02-01), Driedger et al.
patent: 5750568 (1998-05-01), Driedger et al.
patent: 5886017 (1999-03-01), Driedger et al.
patent: 5886019 (1999-03-01), Driedger et al.
patent: 5891870 (1999-04-01), Driedger et al.
patent: 5891906 (1999-04-01), Driedger et al.
patent: 5932613 (1999-08-01), Jiang et al.
patent: 5962498 (1999-10-01), Driedger et al.
patent: 6268395 (2001-07-01), Hattori
patent: 6432452 (2002-08-01), Aylward et al.
patent: 6593371 (2003-07-01), Staggs
patent: 6787161 (2004-09-01), Aylward et al.
patent: 6844013 (2005-01-01), Aylward et al.
patent: 2003/0166613 (2003-09-01), Aylward et al.
patent: 2003/0171334 (2003-09-01), Aylward et al.
patent: 2003/0171337 (2003-09-01), Aylward et al.
patent: 2003/0195168 (2003-10-01), Aylward et al.
patent: 2005/0003031 (2005-01-01), Aylward et al.
patent: 2005/0209192 (2005-09-01), Aylward et al.
patent: 1077129 (1993-10-01), None
patent: 1105246 (1995-07-01), None
patent: 1112011 (1995-11-01), None
patent: 1131037 (1996-09-01), None
patent: 29 02 506 (1979-01-01), None
patent: 0 330 094 (1989-08-01), None
patent: 0 455 271 (1991-11-01), None
patent: 0 310 622 (1992-04-01), None
patent: 8-13571 (1996-01-01), None
patent: 8-176002 (1996-07-01), None
patent: 8-245505 (1996-09-01), None
patent: WO 87/07599 (1987-12-01), None
patent: WO 97/15575 (1997-05-01), None
patent: 99/08994 (1999-02-01), None
M. Belkin et al., “Tumor-Damaging Capacity of Plant Materials”.I. Plants Used as Cathartics, National. Cancer Institute., 13: 139-149 (1952).
D. Weedon et al., “Home Treatment of Basal Cell Carcinoma”,Med. J. Aust., 1:928 (1976).
Uemura, D.. et al., “New Diterpene, 13-Oxyingenol, Derivative Isolated from Euphorbia Kansui Liou”,Tetrahedron Letters29: 2529-2532 (1974).
Kupchan S.M. et al., “Antileukemic Principles Isolated FromEuphorbiaceaePlants”Science, 191: 571-572 (1975).
Kupchan S.M. et al., “Gnidimacrin and Gnidimacrin 20-Palmitate, Novel Macrocyclic Antileukemic Diterpenoid Esters FromGnidia Subcordata”, Communications to the Editor: 5719-5720 (1976).
Evans, F.J. et al., “The Tigliance, Daphane and Ingenane Diterpenes, Their Chemistry, Distribution and Biological Activities, A Review,”Lloydia41(3): 193-233 (1978).
Hecker E., “Structure-Activity Relationships in Diterpene Esters Irritant and Cocarcinogenic to Mouse Skin”,Carcinogenesis2: 11-48 (1978).
Seip E.H. et al., “Skin Irritant Ingenol Esters fromEuphorbia Esula”, Planta Medica46: 215-218 (1982).
Nishizuka Y., “The Role of Protein Kinase C in Cell Surface Signal Tranduction and Tumour Promotion”,Nature308: 693-698 (1984).
Schmidt R.J., “The Ingenane Polyol Esters”,Naturally Occurring Phorbol Esters, Boca Raton: CRC Press: 245-269 (1986).
Inoue S. et al., “Ingenane Synthetic Studies. Sterocontrolled Introduction Of All Oxygenated And Unsaturated Centers In An Ingenol Prototype”,J. Org. Chem. 52: 5497-5498 (1987).
Hamamoto Y. et al., “Comparison of Effects of Protein Kinase C Inhibitors on Phorbol Ester-Induced CD4 Down-Regulation and Augmentation of Human Immunodeficiency Virus Replication In Human Cell Lines”,Biochemical and Biophysical Research Communications 164(1): 339-344 (1989).
Chowdhury I.H. et al., The Phorbol Ester TPA Strongly Inhibits HIV-1-Induced Syncytia Formation but enhances Virus Production: Possible Involvement of Protein Kinase C Pathway,Virology176: 126-132 (1990).
Laurence J. et al., “Phorbol Ester-Mediated Induction of HIV-1 from A Chronically Infected Promonocyte Clone: Blockade by Protein Kinase Inhibotors and Relationships to Tat-Directed Trans-Activation”,Biochemical and Biophysical Research Communications166(1): 349-357 (1990).
Krauter, et al., “Structure/activity relationships of polyfunctional diterpenes of tigliane type”Eur. J. Biochem, 242: 417-427 (1996).
El-Merzabani, et al., “Screening System for Egyptian Plants with Potential Anti-tumour Activity”,Planta Medica.36: 150-155 (1979).
Benjamini, El et al. “Immunology”—A Short Course: 15-18 (1988).
Abo, K.A. “Fitoterpia”, LIX(3): 244-246 (1988).
Alastair Aitken et al., “The Activation of Protein Kinase C by Daphnane, Ingenane and Tigliane Diterpenoid Esters”,Botanical Journal of the Linnean Society, 94: 247-263 (1987).
Sahar El-Mekkaway et al., “Anti-HIV-1 Phorbol Esters from the Seed ofCroton Tiglium”, Phytochemistry, 53: 457-464 (2000).
U.S. Appl. No. 11/324,587, Aylward et al.
Evans, F.J. et al, “Pro-Inflammatory, Tumor-Promoting and Anti-Tumor Diterpenes of the Plant FamiliesEuphoribiaceaeandThymelaeaceae” Department of Pharmacognosy, The School of Pharmacy, University of London, 44: 90-99.
Tian-Shung Wu et al., “Antitumor Agents, 1191Kansuiphorins A and B, Two Novel Antileukemic Diterpene Esters FromEuphorbia Kansui”, Journal of Natural Products, 54(3): 823-829 (1991).
Salah M.A.D. Zayed et al., “Dietary cancer risk from conditional cancerogens in produce of livestock fed on species of spruge (Euphorbiaceae) 1. Skin irritant and tumor promoters of the ingenane diterpene ester type”,Cancer Res. Clin. Oncol, 124: 131-140 (1998).
B D Curti “Physical Barriers to Drug Delivery in Tumors”, Critical Reviews in Onocology/Hematology, 14 : 29-39 (1992).
G. B. Dermer, “Another Anniversary for the War on Cancer”Bio/Technology, 12: 320 (1994).
T. Gura, “Systems for Identifying New Drugs are Often Faulty”,Science, 278: 1041-1042 (1997).
R.I. Freshney, “Culture of Animal Cells, A Manual of Basic Technique”,Department of Clinical Oncology, Cancer Research Campaign Laboratories, University Glasgow.
L H Hartwell, et al. “Integrating Genetic Approaches in the Discovery of Anticancer Drugs,”Science, 278: 1064-1068 (1997).
R K Jain, “Barriers to Drug Delivery in Solid Tumors”,Scientific American: 58-65 (1994).
“Extract from Endocrinology, Proceedings of the American Association for Cancer Research”, 36: 256 (1995).
Hohmann, et al. “Jatrophane Diterpenoids fromEuphorbia peplus”, Phytochemicstry, 51: 673-677 (1999).
Hohmann, et al. “Diterpenoids fromEuphorbia peplus”, Plant Med. 66: 291-294 (2000).
Zayed, et al., Dietry risk from conditional cancerogens in produce of livestock fed on species of spurge (Euphorbiaceae) III. Milk of lactating goats fed on the skin irritant herb Eupho,J. Cancer Research&Clinical Oncology, 124(6): 301-306 (1998).
Zayed, et al., Dietry cancer risk conditional cancerogens in produce of livestock fed on species of spurge (Euphorbiaceae) III. Skin irritant and tumor-promoting ingenane-type diterpene este,J. Cancer Research&Clinical Oncolgy, 124: 131-140 (1998).
Wu et al., Kansuiphorins A and B, two novel antileukemic diterpene esters fromEuphorbia Kansui, Antitumour Agents, J. of Natural Products54(3): 823-829 (1991).
Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 4thEdition (1995): 1314-1323; 1330-1335 and 1590-1603.

Affiliated with

Also associated with

Rating

Treatment of prostate cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of prostate cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of prostate cancer will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3923108